Pure Global

LDL-CHOLESTEROL Direct Method - India CDSCO Medical Device Registration

LDL-CHOLESTEROL Direct Method is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2023/000051_e345189c61147d5beece1f71ab4abb73_8a0b65ead58db7c639a786afdf74a91d. This device is marketed under the brand name BIOLABO ACID CALCIUM Arsenazo III Method. The license holder is Wheecon Instruments Private Limited, and it is classified as Device Class Class B. The approving authority is CDSCO.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class B
LDL-CHOLESTEROL Direct Method
UID: IMP/IVD/2023/000051_e345189c61147d5beece1f71ab4abb73_8a0b65ead58db7c639a786afdf74a91d

Brand Name

BIOLABO ACID CALCIUM Arsenazo III Method

Device Class

Class B

Approving Authority

CDSCO

Product Information

Low density lipoproteins (BIOLABO ACID CALCIUM Arsenazo III Method), are synthesized in the liver by the action of various lipolytic enzymes on triglycerides rich very low density lipoproteins (BIOLABO ACID CALCIUM Arsenazo III Method). Many epidemiological and clinical studies have shown that an increased LDL-Cholesterol is associated with increased risk of atherosclerosis and coronary artery disease (BIOLABO ACID CALCIUM Arsenazo III Method). Some studies showed that a reduction in LDL-Cholesterol is correlated with regression in atherosclerotic lesion

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing